Abstract
Background The selection criterion for hepatic resection(HR) in intermediate-stage(IM) hepatocellular carcinoma(HCC) is still controversial. This study aims to compare transarterial chemoembolisation (TACE) and HR in the range of predicted overall mortality(OM).
Methods In all, 946 consecutive patients with IM-HCC were categorised in HR and TACE group. We performed multivariable Cox regression model to predict OM in HR patients. To evaluate the HR impact on OM concerning baseline characteristics, we test the interaction between predicted OM risk and HR status. The cut-off values were determined by two-piece-wise linear regression model and decision curve analysis. Also, the inverse probability of treatment weight was performed to minimise potential differences as a sensitivity analysis.
Results Totally, 23.0% (n=225) of patients received HR. The 5-yr overall survival rate was higher in the HR group versus the TACE group (52.3% vs 22.8%; P<0.0001). In the HR group, five predictors (all<0.05) were selected to calculate the 5-yr OM risk. This model also used to predict the 5-yr OM-free survival rate. The line of HR and TACE was crossing with predicted OM risk at 100%. The benefit of HR versus TACE decreased progressively as predicted OM risk>55%. When OM risk >80%, HR was not significantly superior to TACE (HR:0.61;95%CI:0.31,1.21), and both HR and TACE did not increase net benefit.
Conclusions Hepatic resection was superior to transarterial chemoembolisation for intermediate-stage hepatocellular carcinoma at the 5-yr OM risk<80%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol (2017-FXY-129) was approved by the Ethics Committee of SYSUCC
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Source of Funding:Dr.Zhu received financial support from the Natural Science Foundation of 900th hospital of PLA (Nos 2016Q05 and 2017Q02 and 2017L17 and 2016L03 and 2017J03).
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare
author affiliations updated
Data Availability
The raw data were freely obtained from the Dryad Digital Repository database (www.Datadryad.org; https://doi.org/10.5061/dryad.pd44k8r).